X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/eisai-to-present-data-on-robust-neurology-portfolio-at-the-76th-american-academy-of-neurology-aan-annual-meeting-302114979.html
https://www.biospectrumasia.com/news/25/24059/french-sales-subsidiary-of-japanese-pharma-firm-eisai-divests-rights-of-neurology-drugs-for-56-5-m.html
https://www.fiercepharma.com/pharma/eisai-biogens-injectable-leqembi-delayed-fda-asks-more-data
https://www.prnewswire.com/news-releases/submission-of-leqembi-lecanemab-irmb-sbla-for-iv-maintenance-dosing-for-the-treatment-of-early-alzheimers-disease-to-the-us-fda-completed-302104249.html
https://www.acnnewswire.com/press-release/english/89970/eisai-to-divest-rights-for-merislon-and-myonal-in-japan-to-kaken-pharmaceutical
https://www.fiercebiotech.com/biotech/new-fda-guidelines-consider-amyloid-reduction-reasonably-likely-predict-clinical-benefit
https://investors.biogen.com/news-releases/news-release-details/eisai-host-annual-information-meeting-update-leqembir-lecanemab
https://www.prnewswire.com/news-releases/bioarctics-partner-eisai-presents-updated-sales-simulation-for-leqembi-at-its-annual-press-conference-302082469.html
https://endpts.com/eisai-delays-alzheimers-patient-goal-deadline-amid-subpar-sales-for-leqembi/
Market Place
Share 
